A collection of peer-reviewed papers and published clinical trials on MUSE (Multilineage-differentiating Stress Enduring) cells, covering areas of ongoing research from cardiac and neurological conditions to skin and neonatal care.
These materials are provided for educational purposes to summarize published research. They are not medical advice, and MUSE cell products are not FDA-approved treatments.
Each study below was published in a peer-reviewed journal. Click through to read the full paper.
Mari Dezawa — Biogerontology, 2025
A review comparing mesenchymal stem cells (MSCs) and Muse cells, covering how Muse cells migrate to damaged tissue and their potential role in anti-aging strategies.
Koda et al. — Stem Cell Research & Therapy, 2024
A phase 1/2a clinical trial in 10 patients with cervical spinal cord injury evaluating the safety and feasibility of a single IV dose of donor Muse cells.
Noda, Nishigaki, Minatoguchi — Circulation Journal, 2020
The first human trial of an allogenic Muse cell product in 3 patients with ST-elevation myocardial infarction, evaluating safety and effects on heart function.
Yamashita et al. — Cell Transplantation, 2023
A phase II trial giving 5 ALS patients repeated monthly Muse cell infusions over 6 months to assess safety, tolerability, and disease progression markers.
Fujita et al. — Journal of the European Academy of Dermatology and Venereology, 2021
A pilot study in 5 adults with dystrophic epidermolysis bullosa testing a single Muse cell infusion for effects on chronic skin ulcers.
Sato, Shimizu et al. — Stem Cells Translational Medicine, 2024
A dose-escalation trial in 9 newborns with hypoxic-ischemic encephalopathy who received Muse cells alongside standard cooling therapy, tracking safety through 78 weeks.
Niizuma et al. — Journal of Cerebral Blood Flow & Metabolism, 2023
A double-blind, placebo-controlled trial in 35 stroke patients comparing a single Muse cell infusion to placebo, measuring safety and functional recovery over 52 weeks.
Mesches, Granholm, Dezawa et al. — Journal of Clinical Medicine, 2026
A review of current cell-replacement approaches for Parkinson’s disease that examines whether Muse cells could offer a distinct option, noting that PD-specific evidence is so far limited to early preclinical work.
Uwishema et al. — International Journal of Emergency Medicine, 2025
A systematic review of 32 studies, including 21 clinical trials and 11 preclinical studies, summarizing how stem cell therapies affected memory, neuroinflammation, and amyloid-beta toxicity in dementia.
If you’d like to talk through what the current research does and doesn’t show, our team is glad to help.
